Fig. 4

Enhanced angiogenic potency of AINs-treated L-ADSCs. A Quantification of human VEGF and FGF2 protein secretion within CM harvested from S-ADSCs at passage 7 without AIN treatment (7 N-CM, 15 N-CM, and 15 A-CM) as evaluated using enzyme-linked immunosorbent assay (ELISA; n = 4, **p < 0.01 versus no treatment group, ^#p < 0.01 versus each group). B Representative profiles of angiogenesis-related proteins secreted from 7 N-CM, 15 N-CM, and 15 A-CM as evaluated using a human angiogenesis antibody array. C Relative mRNA expression of CXCL12 in S-ADSCs and in L-ADSCs with or without AINs treatment. as quantified using qRT-PCR after treatment with AINs for 12 h (n = 4, **p < 0.01 versus no treatment group). D Representative images of scratched area and relative cell migration area after treatment with 7 N-CM, 15 N-CM, and 15 A-CM as analyzed using a scratch wound assay (red area indicates the scratched area, n = 4, **p < 0.01 versus no treatment group)